Will Retatrutide on the market bring down the price of Mounjaro?
Below is the latest schedule of approval for Ret. I'm wondering if we'll see Mounjaro go down in price like what happened to Wegovy?
- NDA Submission (Late 2026 - Q1 2027): Eli Lilly projects that the formal data submissions to the FDA and the EMA will take place following the conclusion of their expansive Phase 3 clinical programs.
- FDA Review (2027–2028): Once submitted, the FDA generally operates on a 10-month standard review period, making late 2027 or early 2028 the most realistic target window for regulatory authorization